We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assay Optimized for Meningitis Bacteria

By LabMedica International staff writers
Posted on 13 Feb 2011
An innovative technique enables the rapid detection of target nucleic acid sequences of Neisseria meningitidis under isothermal conditions without the need for complex instrumentation. More...


A loop-mediated isothermal amplification (LAMP) assay has been developed targeting a cell cycle transcription regulator gene (ctrA), for the rapid detection of capsular N. meningitidis with no cross-reactivity with other Neisseria species or with a comprehensive panel of other common human pathogens.

Scientists at the Royal Victoria Hospital (Belfast, UK), applied the LAMP assay to a total of 394 clinical specimens including samples from serum, ethylenediaminetetraacetic acid (EDTA) anticoagulated blood, throat swabs, cerebrospinal fluid , respiratory secretions, and fecal specimens. The majority of clinical specimens were obtained from pediatric patients who were younger than 13 years old.

An aliquot from each specimen type underwent total nucleic acid extraction, and the DNA extracts were subsequently analyzed in duplicate with a reference externally calibrated quantitative ctrA real-time polymerase chain reaction assay. This test determined meningococcal positivity status and the ctrA gene copy number present for each clinical specimen. The ctrA LAMP primers specifically amplified DNA from eight N. meningitidis-type reference strains. There was a high level of agreement between ctrA LAMP assay and real-time PCR assay with 36/394 positive for both assays and 355/394 negative for both assays.

The authors concluded that the LAMP assay was rapid and highly specific for the detection of all capsular N. meningitidis strains. The test demonstrated sensitivity for clinical specimens of 6 ctrA copies per reaction, which could be detected within 48 minutes and higher copy numbers could be detected in as little as 16 minutes.

The LAMP assay was simple to use and did not require specialized equipment, with positive specimens being readily identified by visual observation of color change or turbidity. This LAMP assay has the potential to be used for rapid detection of pathogenic meningococci in laboratories that do not have the instruments or expertise to perform real-time PCR. The study was published in February 2011 in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Royal Victoria Hospital




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.